Company profile
SIGA TECHNOLOGIES INC
NASDAQ:SIGABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TPOXX | approved | — | 5 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02474589 | phase3 | completed | 2015-06-19 | 2016-08-24 | SIGA Technologies | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat |
| NCT04485039 | phase4 | completed | 2022-06-08 | 2022-12-15 | SIGA Technologies | Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders |
| NCT00728689 | phase1 | completed | 2008-08-01 | 2008-10-01 | SIGA Technologies | Phase I Trial of an Investigational Small Pox Medication |
| NCT00431951 | phase1 | completed | 2007-02-01 | 2008-02-01 | SIGA Technologies | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers |
| NCT04392739 | phase4 | completed | 2019-07-19 | 2019-12-05 | SIGA Technologies | Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 214518 | 2022-05-18 | NDA | SIGA TECHNOLOGIES INC | |||||
Loading… | ||||||||
| NDA 208627 | 2018-07-13 | NDA | SIGA TECHNOLOGIES INC | |||||
Loading… | ||||||||